SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about inspection updates

18 Apr 2026 Evaluate
Lupin has informed that the US FDA has concluded an inspection at manufacturing facility located in Somerset, New Jersey, USA. The inspection was conducted from April 13, 2026 to April 17, 2026 and closed with the issuance of a Form-483 with three observations. They will address the observations and respond to the US FDA within the stipulated timeframe. They are committed to be compliant with CGMP standards across all its facilities. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×